A Different Kind of Drug-Device Convergence
This article was originally published in Start Up
Executive Summary
The recently-announced agreement between atherectomy leader FoxHollow Technologies and pharmaceutical giant Merck has highlighted what could increasingly be a lucrative opportunity for some deevice companies in the whole field of convergence: service-based collaborations with drug companies engaged in clinical trials for cardiovascular and other types of drugs to provide the kinds of analytical tools or materials to richly inform and make more efficient such trials.